| HOME >> MEDICINE >> TECHNOLOGY |
Quark's Novel siRNA Structures Exhibit Stability and Activity in vitro
FREMONT, Calif., Aug. 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that the Company has filed a patent application covering a number of novel chemical modifications that confer to the siRNA molecule stability and excellent penetration into the human cells tested.
"With the submission of this patent application, we believe we have provided significant additional protection for our pipeline program," said Daniel Zurr, President and CEO of Quark. "Filing of this patent application marks a significant step in our efforts to solidify our position as a leader in the RNAi therapeutics space, as the new structures allow us more flexibility with regard to intellectual property. We believe our future siRNA therapeutics will be less dependent on in-licensed rights to RNAi technology. This patent application adds the element of structural design to our expertise in identifying clinically attractive drug targets using a proprietary discovery platform and local or systemic delivery."
The patent application relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop novel synthetic siRNA patterns with drug-like properties as well as improved targeted delivery systems.
Currently, Quark owns or controls 30 issued U.S. and European patents, and has 200 patent applications pending, covering its technology, drug candidates, target genes and pipeline products.
About Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on developing drug candidates that
'/>"/>
| SOURCE Quark Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |